Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Naloxone Clear all
Terminated Not applicable Interventional Results available

Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain

NCT00716807
View directory record Official record
Conditions
Temporomandibular Joint Dysfunction Syndrome, Burning Mouth Syndrome
Interventions
nalbuphine plus naloxone, nalbuphine plus placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 3 Interventional Results available

Prescription Opioid Addiction Treatment Study (POATS)

NCT00316277
View directory record Official record
Conditions
Opiate Dependence, Substance-related Disorders, Opioid-related Disorders
Interventions
Standard Medical Management (SMM) of Prescription Opiate Abuse, Enhanced Medical Management (EMM) of Prescription Opiate Abuse
Behavioral
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Lawrenceburg, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Jul 23, 2026, 6:24 AM EDT
Completed No phase listed Observational

Increasing Patient Knowledge of the Signs of Opioid Overdose and Naloxone in a Suburban Treatment Program

NCT02120612
View directory record Official record
Conditions
Opioid Dependence, Opioid Use Disorder
Interventions
Naloxone Education Intervention
Other
Lead sponsor
Edward Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Naperville, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Not applicable Interventional Results available

Comparison of Two Naloxone Infusion Rates on the Postoperative Recovery of Patients Undergoing Spine Fusion Surgery

NCT01531439
View directory record Official record
Conditions
Pain, Postoperative, Postoperative Nausea and Vomiting, Scoliosis
Interventions
Naloxone
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
10 Years to 21 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence

NCT01848054
View directory record Official record
Conditions
Opioid-Related Disorders, Opiate Dependence
Interventions
Buprenorphine/naloxone sublingual tablets, Buprenorphine
Drug
Lead sponsor
Orexo AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
14
States / cities
Birmingham, Alabama • Haleyville, Alabama • National City, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 2 Interventional

Cariprazine for Comorbid Cocaine and Opioid Use Disorder

NCT05063201
View directory record Official record
Conditions
Opioid-use Disorder, Cocaine Use Disorder
Interventions
Cariprazine 1.5 MG, Placebo
Drug
Lead sponsor
Kyle Kampman
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jul 23, 2026, 6:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Assess the PK Profile of NanoBUP Capsules Relative to Suboxone

NCT01260675
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine HCl/Naloxone HCl
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/Ritonavir

NCT00486330
View directory record Official record
Conditions
HIV Infections
Interventions
Buprenorphine, Tipranavir and ritonavir
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 19, 2020 · Synced Jul 23, 2026, 6:24 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

RESPOND TO PREVENT: Stepwise Pharmacy Naloxone Study

NCT03545321
View directory record Official record
Conditions
Pharmacies, Opioid Use, Patient Safety
Interventions
MOON+
Behavioral
Lead sponsor
Brandeis University
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
5
States / cities
Waltham, Massachusetts • Portland, Oregon • Kingston, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Opioid Antagonism in Individuals Ascertained Through the Partners HealthCare Biobank

NCT04975347
View directory record Official record
Conditions
Reproductive Disorders
Interventions
Naloxone
Drug
Lead sponsor
Stephanie B. Seminara, MD
Other
Eligibility
18 Years to 60 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neuropeptides in Human Reproduction

NCT01952782
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
Kisspeptin 112-121, Naloxone, GnRH
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Jul 23, 2026, 6:24 AM EDT
Terminated Phase 2 Interventional Results available

Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia

NCT03066739
View directory record Official record
Conditions
Hyperalgesia
Interventions
Remifentanil, Remifentanil+ Placebo, Remifentanil +ultra-low dose naloxone
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Bioavailability of Naloxone Nasal Spray and Naloxone Hydrochloride (HCl) Intramuscular Injection (IM) in Healthy Volunteers

NCT03827629
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Treatment A: Naloxone Nasal Spray, Treatment B: Naloxone Nasal Spray, Treatment C: Naloxone HCL Intramuscular (IM) Injection
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Clinical Study to Investigate the Pharmacokinetics of Multiple Repeated Doses of Intranasal Naloxone

NCT04764630
View directory record Official record
Conditions
Healthy Subjects, Opioid Antagonist, Pharmacokinetics
Interventions
Four naloxone nasal spray doses (1 every 2.5 min), Four naloxone nasal spray doses (2 every 2.5 min), Two naloxone nasal spray doses (1 every 2.5 min)
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Jul 23, 2026, 6:24 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prevention

NCT06852170
View directory record Official record
Conditions
Substance Abuse, Decision Making, Shared, Implementation Science, Decision Making, Organizations, Substance-related Disorders, Policy
Interventions
Co-Design Sessions (CDS), Data products
Other
Lead sponsor
Chestnut Health Systems
Other
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone

NCT01760473
View directory record Official record
Conditions
Heroin Dependence
Interventions
Intranasal challenge drug
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Not applicable Interventional

Buprenorphine and Substance Abuse Services for Prescription Opioid Dependence

NCT02496403
View directory record Official record
Conditions
Opiate Substitution Treatment
Interventions
Standard Medical Management (SMM)
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of Naloxone Pharmacokinetics

NCT03386591
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Naloxone, Mucosal atomization device and syringe, Narcan, Intramuscular Auto Injector
Drug · Device
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Jul 23, 2026, 6:24 AM EDT
Active, not recruiting Not applicable Interventional Results available

HEALing Communities Study

NCT04111939
View directory record Official record
Conditions
Opioid Use Disorder (OUD)
Interventions
Communities That HEAL, Wait-list control
Other
Lead sponsor
RTI International
Other
Eligibility
Not listed
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
4
States / cities
Lexington, Kentucky • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 3 Interventional

Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1

NCT00032955
View directory record Official record
Conditions
Heroin Dependence, Morphine Dependence, Substance Withdrawal Syndrome
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
15 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
6
States / cities
Rancho Mirage, California • Orlando, Florida • Pinellas Park, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jul 23, 2026, 6:24 AM EDT
Not listed Not applicable Interventional

The Impact of a Web-Based Naloxone Intervention Under Standing Orders to Patients Prescribed Chronic Opioid Therapy

NCT03337009
View directory record Official record
Conditions
Overdose, Risk Behavior
Interventions
Naloxone Navigator (NN)
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
1,004 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 19, 2024 · Synced Jul 23, 2026, 6:24 AM EDT
Withdrawn Phase 2 Interventional

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5

NCT00000330
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Opioid-Related Disorders
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Jul 23, 2026, 6:24 AM EDT
Terminated Phase 2 Interventional

Abuse Potential of Buprenorphine/Naloxone

NCT00149539
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jul 23, 2026, 6:24 AM EDT
Active, not recruiting Not applicable Interventional

The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City

NCT06316739
View directory record Official record
Conditions
HIV Infections, HCV, Overdose
Interventions
Ganchero intervention
Behavioral
Lead sponsor
North Jersey AIDS Alliance dba North Jersey Community Research Initiative (NJCRI)
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Jul 23, 2026, 6:24 AM EDT